Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. It is available in oral and intravenous formulations.
## Primary Indications
* Erosive esophagitis associated with GERD
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Gastroesophageal reflux disease (GERD) - symptom relief and maintenance of healing
## Adult Dosing
**Oral:**
* **GERD (healing):** 20 mg once daily for up to 8 weeks.
* **GERD (maintenance):** 10 mg once daily (may increase to 20 mg if needed).
* **Erosive esophagitis:** 40 mg once daily for 4-8 weeks.
* **Pathological hypersecretory conditions:** Starting dose 40 mg twice daily; titrate as needed. Doses up to 240 mg daily have been administered intravenously.
**Intravenous (IV):**
* **Healing erosive esophagitis:** 40 mg once daily for 7-10 days.
* **Pathological hypersecretory conditions:** 40 mg every 8 hours; titrate as needed.
## Pediatric Dosing
**Oral:**
* **GERD (ages 5-11 years):** 20 mg once daily for up to 8 weeks.
* **GERD (ages 12-16 years):** 40 mg once daily for up to 8 weeks.
**Intravenous (IV):**
* **GERD (ages 5-15 years):** 20 mg once daily for up to 7 days.
*Note: Dosing in pediatric patients may vary based on institutional protocols and specific clinical guidelines.*
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, although caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with increased risk of bone fractures, Clostridium difficile infection, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with other drugs metabolized by this enzyme (e.g., clopidogrel, warfarin).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, seizures, arrhythmias).
* Monitor for signs of C. difficile infection.
* Long-term use may warrant monitoring of magnesium and vitamin B12 levels.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV pantoprazole should be administered as an infusion over 15 minutes.
* When switching from IV to oral, the total daily dose should remain the same.
* Long-term PPI therapy should be used at the lowest effective dose.
***
**Disclaimer:** This information is intended for healthcare professionals and should not be considered a substitute for professional medical advice. Always consult current prescribing information and relevant clinical guidelines before making any treatment decisions.
